Oral anabolic steroid
Primobolan Oral
Oral methenolone acetate (Primobolan tablets) is an anabolic steroid whose Japanese label gives 10 to 20 mg a day; none of the sources cited reports its half-life.1
Primobolan Oral after one dose: 50% at ~7 h, 25% at 14 h, 12.5% at 21 h.
Drawn from the half-life in the app's model, ~7 h. The model's figures
- Compound
- Primobolan Oral
- Symbol
- PRO
- Family
- Other steroids
- Parts
- 14
- References
- 11
- Checked
- Last reviewed . Sources are listed below.
Overview
Methenolone acetate, sold as Primobolan tablets, is a synthetic anabolic steroid and an agonist of the androgen receptor.2 The Japanese label gives its chemical name as 1-Methyl-3-oxo-5α-androst-1-en-17β-yl acetate and its molecular weight as 344.49.1 In 1975 Walker and colleagues, assessing six anabolic steroids in men with ischaemic heart disease, described methenolone acetate as the only non-17alpha-alkylated steroid among them.3
The Bayer Yakuhin label for Primobolan tablets 5 mg, revised in August 2020, lists osteoporosis, marked wasting states from chronic kidney disease, malignant tumour, trauma or burns, and bone marrow wasting from aplastic anaemia as its indications (translated from the Japanese).1 The authors of a 2024 case report from Kawasaki Municipal Tama Hospital write that it is still used in Japan in the treatment of anemia due to bone marrow failure, unlike in Europe and the United States, where it is no longer used for this purpose.2 The human evidence cited below is a randomised trial of oral methenolone in aplastic anaemia, a clinical trial of fibrinolysis, two excretion studies, a urine study of men who ate meat from treated chickens and three case reports.4,3,5,6,7,2,8,11 A search of PubMed on 16 November 2026 for methenolone or metenolone with acetate in the title or summary text returned 48 records. The 1988 trial's record names the drug as methenolone without the ester, so that search does not capture it.
How it works
Sources in this part
The Japanese label states that the drug promotes protein synthesis in the liver and tissues, suppresses the breakdown of body protein and promotes deposition of calcium and phosphorus in tissues (translated).1 Ushimaru and colleagues, in the 2024 case report, write that methenolone acetate is an agonist of the androgen receptor, the biological target of androgens such as testosterone and dihydrotestosterone.2 They also write that its effects on bone are mediated through its androgenic properties without estrogenic effect; they reach this after citing the androgen receptor's lack of direct action on osteoclasts in an animal model study, and nothing in the patient's case measured it.2 The label reports measurements in healthy people and in people with osteoporosis, gonadal insufficiency and muscle disease, without stating how many were studied.1 In these groups 20 to 30 mg a day by mouth (330 mg in total) retained 47.1 mg/kg/day of nitrogen, and 20 to 30 mg a day (300 to 360 mg in total) retained 1.26 mg/kg/day of calcium and 2.75 mg/kg/day of phosphorus.1 At 20 mg a day for 28 days by mouth, haemoglobin and red cell counts rose.1
Pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~7 h
- Bioavailability
- 3%
- Typical dose
- 10–50 mg/day
- Route
- Oral
- Time to peak
- ~2 h
A search of PubMed on 16 November 2026 for methenolone, metenolone or Primobolan with pharmacokinetic, bioavailability or half-life terms in the title or summary text returned 1 record, a 2023 doping-control paper on detection times of sulphated metabolites. None of the sources cited reports a plasma half-life, time to peak, bioavailability or duration of activity for methenolone acetate, so the excretion data that were measured are listed beside the app's figures.
| Parameter | Value | Note |
|---|---|---|
| Half-life | ~7 hours | The app's figure. None of the sources cited reports a half-life. |
| Time to peak | ~2 hours | The app's figure. None of the sources cited reports one. |
| Bioavailability | ~3% | The app's figure. None of the sources cited reports bioavailability; the excretion rows below are different measures. |
| Duration of activity | ~12 hours | The app's figure. None of the sources cited reports one. |
| Parent drug in urine5 | 1.63% of the ingested dose | Cumulative urinary excretion of methenolone after a 50 mg oral dose in two men; methenolone was detected in urine until 90 hours. |
| Radiolabelled dose excreted1 | 21 to 47% in urine and 14 to 22% in faeces | Within 7 to 13 days of a 114 mg oral dose of [14C]-methenolone acetate in four healthy men; the label marks this as non-Japanese data. |
| Main urinary metabolite6 | Significant amounts detected for 5 days | 3α-hydroxy-1-methylen-5α-androstan-17-one after a single oral 10 mg ingestion; the method identified and quantitated it at concentrations exceeding 10 ng/mL. |
| Route | Oral | The Japanese label gives oral administration, as tablets. |
| Typical dose | 10 to 50 mg/day | The app's figure. The Japanese label gives 10 to 20 mg a day, and 50 mg appears in the cited sources as the dose given to two volunteers. |
The chart below draws a curve from the app's half-life of 7 hours and time to peak of 2 hours; its one daily schedule is the 20 mg/day of the 2024 case report.2
Level over 4 days
Level, as a share of the peak after one 20 mg dose
As studied: daily2.
An illustration from a pharmacokinetic model using a half-life of 7 hours. It is not a measured level or a suggested dose.
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Kaltwasser and colleagues, 19884 | Prospective, randomised; antithymocyte globulin (ATG) with or without oral methenolone; the record names no sponsor | 30 patients with aplastic anaemia, 18 of them severe | Methenolone 3 mg/kg by mouth with ATG 100 mg/kg; length not stated in the record | Responses in 11 of 15 with methenolone (73%) against 4 of 15 without (reported as 31%), p = 0.01; survival 87% against 43%, p = 0.15. |
| Walker and colleagues, 19753 | Clinical trial of six anabolic steroids and plasma fibrinolytic activity | Men with ischaemic heart disease; number not stated in the record | Dose and length not stated in the record | Methenolone acetate failed to enhance fibrinolysis; the five 17alpha-alkylated steroids each raised plasma plasminogen activator significantly. |
| Goudreault and Massé, 19905 | Human metabolism study with urine analysed by gas chromatography and mass spectrometry | 2 male volunteers | A 50 mg oral dose; length not stated in the record | Twelve urinary metabolites; methenolone detected until 90 hours; 1.63% of the ingested dose excreted as methenolone. |
| Björkhem and Ek, 19836 | Isotope dilution mass spectrometry method, applied to urine after an oral dose and to athletes' samples | Number not stated in the record | A single oral 10 mg ingestion | Significant amounts of the major urinary metabolite were detected for 5 days. |
| Tsukamoto and colleagues, 19937 | Case report | 1 man aged 75 with severe aplastic anemia | Metenolone acetate after cyclosporin A and steroid pulse therapy; route, dose and length not stated in the record | Marked transaminase elevation, then hepatic failure and death. |
| Ushimaru and colleagues, 20242 | Retrospective case report | 1 man aged 73 with stage 4 chronic kidney disease and myelodysplastic syndrome | 20 mg/day by mouth with darbepoetin, followed for 2 years | Haemoglobin 7.6 g/dL before treatment, 9.1 at 1 month, 12.6 at 2 years; lumbar spine BMD change slowed from -4.4% to -2.9% a year. |
| Sonmez and colleagues, 20168 | Case report | 1 man aged 32 using methenolone acetate for body building | 200 mg weekly for 3 years; route not stated in the record | Severe chest pain and raised cardiac markers, with normal coronary arteries on angiogram. |
Deeper analysis: Kaltwasser and colleagues, 1988
Kaltwasser and colleagues, of the Department of Haematology at J.W. Goethe University in Frankfurt, published this trial in the European Journal of Haematology in 1988.4 They randomised 30 patients with aplastic anaemia to antithymocyte globulin with or without oral methenolone at 3 mg/kg, and the record calls the drug methenolone without naming the ester.4 Fifteen of the 30 patients responded: 11 of 15 (73%) with methenolone, including 8 complete and 3 partial responses, and 4 of 15 (reported as 31%) without it, including 2 complete and 2 partial responses (p = 0.01).4 Survival was 87% with methenolone and 43% without, and the authors state that this difference did not reach statistical significance (p = 0.15).4 They report that toxicity of the antithymocyte globulin and the androgens together was considerable but manageable, without separating the two.4 Their own stated limit is that "Further controlled studies on a larger number of patients are indicated", and they note that the result contradicts a controlled American study showing no benefit of combined treatment with androgens.4 The PubMed record lists the publication type Research Support, Non-U.S. Gov't and names no sponsor or author tie.4
Deeper analysis: Goudreault and Massé, 1990
Goudreault and Massé, of the Institut National de la Recherche Scientifique (Université du Québec), reported the metabolism of methenolone acetate in the Journal of Steroid Biochemistry and Molecular Biology in 1990.5 After a 50 mg oral dose to two male volunteers they detected twelve metabolites in urine, with 3α-hydroxy-1-methylen-5α-androstan-17-one the major one.5 Methenolone itself was detected until 90 hours, and its cumulative urinary excretion was 1.63% of the ingested dose, which differs from the app's 3% bioavailability, though the two measure different things.5 The authors conclude that the drug was metabolised by oxidation of the 17-hydroxyl group and reduction of A-ring substituents, with or without hydroxylation at C6 and C16.5 The record states no limitations and names no funder; its publication type is Research Support, Non-U.S. Gov't.5
Deeper analysis: Ushimaru and colleagues, 2024
Ushimaru and colleagues, of Kawasaki Municipal Tama Hospital and St. Marianna University, reported in JCEM Case Reports in 2024 a 73-year-old man with stage 4 chronic kidney disease and myelodysplastic syndrome (refractory cytopenia with multilineage dysplasia).2 He received methenolone acetate 20 mg/day by mouth with darbepoetin 480 μg/month subcutaneously.2 Haemoglobin rose from 7.6 g/dL to 9.1 g/dL at 1 month and 12.6 g/dL at 2 years, although the authors observed no improvement in the myelodysplastic syndrome.2 Bone mineral density had fallen at each site by the scan 1 month after treatment began, and afterwards the lumbar decline slowed to -2.9% a year, the right femoral neck changed by +1.1% a year and the left by -0.2% a year; bone alkaline phosphatase rose to 28.4 μg/L and TRACP-5b to 1110 mU/dL.2 No new fractures were detected, and the authors report no side effects such as raised prostate-specific antigen or liver dysfunction.2 Their stated limit is that "Owing to the retrospective nature of this case report, it is impossible to address the causality between anemia treatment and attenuation of BMD decline"; darbepoetin was given at the same time.2 The report states "No public or commercial funding" and "Disclosures None declared".2
Deeper analysis: Tsukamoto and colleagues, 1993
Tsukamoto and colleagues, of Takasaki National Hospital, reported in the Annals of Hematology in 1993 a 75-year-old man with severe aplastic anemia treated first with cyclosporin A, then with steroid pulse therapy, and then with metenolone acetate.7 Marked elevation of transaminases followed the start of metenolone acetate, then hepatic failure and death.7 The authors state that autopsy findings were compatible with drug-induced liver impairment and that metenolone acetate was considered the most likely causative agent, and that liver impairment from the drug had been thought to be mild, reversible and rather infrequent, but that this case shows extreme caution is called for when the drug is used in debilitated patients.7 The record names no funder and no author tie and does not state the route, dose or length; the patient had also received cyclosporin A and steroid pulse therapy before it.7
Doses reported in studies and on labels
The label's usual adult dose is 10 to 20 mg a day, and its other rows are pharmacology and excretion measurements at the doses shown.1
| Source | Dose | Frequency | Length |
|---|---|---|---|
| Japanese label, usual adult dose1 | 10 to 20 mg a day, increased or decreased by age and symptoms | 2 to 3 divided oral doses a day | Not stated |
| Japanese label, nitrogen retention1 | 20 to 30 mg a day (330 mg in total) | Not stated; by mouth | Not stated |
| Japanese label, calcium and phosphorus retention1 | 20 to 30 mg a day (300 to 360 mg in total) | Not stated; by mouth | Not stated |
| Japanese label, haemoglobin and red cells1 | 20 mg a day | By mouth, daily | 28 days |
| Japanese label, radiolabelled excretion1 | 114 mg of [14C]-methenolone acetate; the label notes the approved dose is 10 to 20 mg a day | Once | Urine and faeces followed for 7 to 13 days |
| Kaltwasser and colleagues, 19884 | Methenolone 3 mg/kg with ATG 100 mg/kg | Not stated | Not stated |
| Goudreault and Massé, 19905 | 50 mg by mouth | Not stated | Urine followed for 90 hours |
| Björkhem and Ek, 19836 | 10 mg by mouth | Single ingestion | Urine followed for 5 days |
| Ushimaru and colleagues, 20242 | 20 mg/day by mouth | Daily | 2 years of follow-up |
| Sonmez and colleagues, 20168 | 200 mg; route not stated in the record | Weekly | 3 years |
Side effects reported
The Japanese label lists hepatic dysfunction with marked rises in AST, ALT and γ-GTP, and jaundice, as serious adverse reactions, each with frequency unknown (translated).1 It also lists, with frequency unknown, hypersensitivity, raised AST and ALT, and nausea and vomiting.1 In women it lists hoarseness (which may be hard to recover from if it advances), excess hair growth, acne, pigmentation, menstrual abnormalities, clitoral enlargement and increased libido.1 In men it lists acne, penile enlargement, impotence, persistent erection and, with continued large doses, suppression of testicular function such as reduced sperm and semen.1 Its other precautions state that liver tumours have been reported in patients with aplastic anaemia and others given anabolic steroids long term at large doses.1
For children the label lists premature epiphyseal closure and sexual precocity, for heart or kidney disease sodium or fluid retention, for diabetes reduced glucose tolerance, and for pregnancy a risk of masculinising a female fetus.1 It lists pregnant women and women who may be pregnant, and androgen-dependent malignant tumours such as prostate cancer and suspicion of them, among its contraindications.1 Under interactions it names corticosteroids, which may reduce glucose tolerance, and coumarin anticoagulants such as warfarin, whose effects may be enhanced, in both cases with the mechanism unknown.1
Among the case reports, the 1993 patient developed hepatic failure and died, and the authors write that liver impairment from the drug had been thought to be mild, reversible and rather infrequent, but that this case shows extreme caution is called for when the drug is used in debilitated patients.7 The 2024 authors report no liver dysfunction or raised prostate-specific antigen in their patient.2 A 32-year-old man who had taken methenolone acetate 200 mg weekly for three years had chest pain and raised cardiac markers with normal coronary arteries, and the authors, who title the report as chronic anabolic androgenic steroid usage associated with acute coronary syndrome, present this as anabolic steroid-induced myocardial infarction.8 In the 1988 trial the authors describe the toxicity of antithymocyte globulin and the androgens together as considerable but manageable.4
Bloodwork and markers
Sources in this part
The app lists liver enzymes, lipids and hematocrit as markers to monitor. Liver enzymes appear in the label's adverse reactions and in the fatal 1993 case, and haemoglobin and red cell counts in the label's pharmacology and in the 2024 case.1,7,2 None of the sources cited reports lipids or haematocrit for methenolone acetate. The label's precautions list periodic prostate examination for men and, especially in long-term use, periodic laboratory tests such as liver function tests (translated).1 In the 2024 case, bone alkaline phosphatase was 10.8 μg/L and TRACP-5b 550 mU/dL at the first assessment, 1 year and 10 months before treatment, then 14.9 and 841 at 1 month of treatment and 28.4 and 1110 at 2 years.2
Regulatory and anti-doping status
The Japanese label is for Primobolan tablets 5 mg from Bayer Yakuhin, marked as a prescription drug.1 The WADA 2026 Prohibited List, in effect from 1 January 2026, names metenolone, the list's spelling, in S1.1 among anabolic androgenic steroids when administered exogenously.9 S1 is prohibited at all times, in and out of competition, and all prohibited substances in the class are non-Specified Substances.9 The class also covers other substances with a similar chemical structure or similar biological effect, including their esters.9 In the United States, 21 CFR 1308.13(f) lists methenolone among the anabolic steroids in Schedule III, including its salts, esters and ethers.10 Kicman and colleagues of the Drug Control Centre, King's College London, analysed urine from eight men who ate chickens fed methenolone acetate at 1 mg/day or injected with methenolone heptanoate.11 No methenolone or characteristic major metabolite was detected after meat from the orally dosed chickens, while 50% of samples collected 24 hours after eating the injected chickens were confirmed positive.11
Storage and handling
Sources in this part
The Japanese label states that the tablets are to be stored protected from light once the outer box is unsealed, and lists packs of 100 tablets as 10 PTP sheets of 10 tablets.1
What is not known
None of the sources cited states a plasma half-life, time to peak, bioavailability or duration of activity for methenolone acetate, so the app's figures of ~7 hours, ~2 hours, 3% and ~12 hours have no figure from a cited source beside them. The 1988 trial's record names the drug as methenolone and gives no length of treatment.4 None of the studies cited measures muscle mass or athletic performance with oral methenolone acetate. The label's pharmacology figures give no number of people, and the case reports each describe one person.1 The liver safety information cited rests on the label, one fatal case report (route not stated in the record) and one case without liver dysfunction.1,7,2
Frequently asked questions
What is oral Primobolan?
What is the half-life of oral Primobolan?
The app lists a half-life of about 7 hours for oral Primobolan, and none of the sources cited reports one. After a 50 mg oral dose in two men, methenolone was still detected in urine at 90 hours, which is an excretion finding and not a half-life.5
What is the bioavailability of oral Primobolan?
The app lists a bioavailability of about 3% for oral Primobolan, and none of the sources cited reports one. In the 1990 study 1.63% of a 50 mg oral dose was excreted in urine as methenolone, and the label reports that 21 to 47% of a 114 mg radiolabelled dose appeared in urine and 14 to 22% in faeces within 7 to 13 days.5,1
What dose of oral Primobolan is on the label?
The Japanese label gives a usual adult dose of 10 to 20 mg a day in 2 to 3 divided oral doses, increased or decreased by age and symptoms (translated).1 The app lists a typical dose of 10 to 50 mg/day.
Is oral Primobolan 17-alpha alkylated?
Is oral Primobolan liver toxic?
The Japanese label lists hepatic dysfunction and jaundice among serious adverse reactions, with frequency unknown (translated).1 A 1993 case report (route not stated in the record) describes marked transaminase elevation, hepatic failure and death in a 75-year-old man with severe aplastic anemia after metenolone acetate, while a 2024 case report of a 73-year-old man on 20 mg/day reported no liver dysfunction.7,2
Is oral Primobolan banned by WADA?
The WADA 2026 Prohibited List names metenolone in S1.1, anabolic androgenic steroids when administered exogenously, a class prohibited at all times, in and out of competition.9
Is oral Primobolan a controlled substance in the United States?
21 CFR 1308.13(f) lists methenolone, including its salts, esters and ethers, among the anabolic steroids in Schedule III.10
What has been studied with oral methenolone?
The one randomised trial cited here, by Kaltwasser and colleagues, randomised 30 patients with aplastic anaemia to antithymocyte globulin with or without oral methenolone, and 11 of 15 responded with it against 4 of 15 without (p = 0.01).4 Survival differed (87% against 43%) without reaching statistical significance (p = 0.15).4 The authors describe the toxicity of antithymocyte globulin and the androgens together as considerable but manageable, and write that further controlled studies on a larger number of patients are indicated.4
Guides, tools and comparisons
References
- Bayer Yakuhin. Primobolan tablets 5 mg (metenolone acetate): package insert (Japanese), revised August 2020; JAPIC data shown in KEGG MEDICUS. Japanese label (KEGG MEDICUS)
- Ushimaru S, et al. Attenuation of Bone Mineral Density Decline During Anemia Treatment With Methenolone Acetate in Myelodysplastic Syndrome. JCEM Case Rep 2024. PMC11017109
- Walker ID, et al. Plasma fibrinolytic activity following oral anabolic steroid therapy. Thromb Diath Haemorrh 1975. PMID 1103357
- Kaltwasser JP, et al. Effect of androgens on the response to antithymocyte globulin in patients with aplastic anaemia. Eur J Haematol 1988. PMID 3278927
- Goudreault D, Massé R. Studies on anabolic steroids--4. Identification of new urinary metabolites of methenolone acetate (Primobolan) in human by gas chromatography/mass spectrometry. J Steroid Biochem Mol Biol 1990. PMID 2242348
- Björkhem I, Ek H. Detection and quantitation of 3 alpha-hydroxy-1-methylen-5 alpha-androstan-17-one, the major urinary metabolite of methenolone acetate (Primobolan) by isotope dilution--mass spectrometry. J Steroid Biochem 1983. PMID 6339822
- Tsukamoto N, et al. Fatal outcome of a patient with severe aplastic anemia after treatment with metenolone acetate. Ann Hematol 1993. PMID 8334198
- Sonmez E, et al. Chronic anabolic androgenic steroid usage associated with acute coronary syndrome in bodybuilder. Turk J Emerg Med 2016. PMID 27239638
- World Anti-Doping Agency. Prohibited List 2026, in effect from 1 January 2026. WADA list
- US Code of Federal Regulations. Title 21, section 1308.13, Schedule III (eCFR, version of 1 November 2026). 21 CFR 1308.13
- Kicman AT, et al. Effect on sports drug tests of ingesting meat from steroid (methenolone)-treated livestock. Clin Chem 1994. PMID 7955383